리포솜 독소루비신 시장 규모, 점유율, 성장 분석 : 제품 유형별, 용도별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Liposomal Doxorubicin Market size was valued at USD 1.28 Billion in 2024 and is poised to grow from USD 1.36 Billion in 2025 to USD 2.24 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and its effectiveness in treating various cancers, including breast and ovarian cancer. This formulation, encapsulated in a lipid sphere, enhances drug delivery, spurring demand. Key growth factors include advancements in healthcare infrastructure, escalating healthcare expenditures, heightened patient awareness regarding treatment options, and the proliferation of generic alternatives. However, intensified competition from generics and stringent regulatory requirements may pose challenges to market expansion. Nonetheless, the sector's profitability is expected to flourish due to increased awareness of viable treatment alternatives and growing investments from both public and private sectors. Additionally, rising incidences of hepatocellular carcinoma and challenges in previous treatments for specific cancers further boost demand for liposomal doxorubicin.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segments Analysis

Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liposomal Doxorubicin Market

The global market for liposomal doxorubicin is significantly driven by its primary application in breast cancer treatment, which is witnessing alarming growth in numerous countries. A key factor contributing to the rising popularity of this drug is the ongoing innovation in formulations. Moreover, there is an increasing demand for pharmaceuticals designed for targeted therapies, coupled with a growing reliance on chemotherapy. Private sector investments in this area are also escalating, further supporting market expansion. Additionally, government initiatives to bolster the healthcare industry play an essential role in enhancing the global presence of liposomal doxorubicin, thereby propelling its market growth.

Restraints in the Global Liposomal Doxorubicin Market

The global liposomal doxorubicin market may face significant challenges due to various adverse effects associated with the medication. Patients may experience an elevated risk of infections, respiratory difficulties, pallor, easy bruising, frequent nosebleeds, and overall weakness before and after treatment. Additional side effects may include redness, pain, and peeling of the hands and feet, along with symptoms such as weight loss, diarrhea, and fatigue. These complications can deter patient adherence to treatment and may lead to reluctance among healthcare providers to prescribe liposomal doxorubicin, ultimately hindering the growth of the market.

Market Trends of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is witnessing a notable upward trend, primarily driven by the rising incidence of breast cancer, which constitutes a significant portion of cancer diagnoses among women globally. Increasing awareness and advancements in targeted drug delivery systems, coupled with a growing preference for liposomal formulations due to their enhanced bioavailability and reduced side effects, are bolstering market growth. Additionally, ongoing research into the efficacy of liposomal doxorubicin in treating various malignancies beyond breast cancer is further diversifying its application. This evolving landscape indicates a robust potential for sustained expansion in the liposomal doxorubicin sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Lipodox
• Doxil
• Myocet

Global Liposomal Doxorubicin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Ovarian Cancer
• Multiple Myeloma
• Kaposi's Sarcoma
• Other Cancers

Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Liposomal Doxorubicin Market Size & CAGR (2026-2033)

• North America (Product Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SRS Pharmaceuticals Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations